KindlyMD, Inc. (NASDAQ:NAKA) Receives $30.00 Average Price Target from Brokerages

KindlyMD, Inc. (NASDAQ:NAKA) has earned a consensus rating of “Hold” from the five brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $30.00.

A number of equities research analysts recently commented on NAKA shares. B. Riley Financial decreased their price target on KindlyMD from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, February 23rd. Maxim Group decreased their price target on KindlyMD from $60.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Wall Street Zen upgraded KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. TD Cowen started coverage on KindlyMD in a research report on Friday, April 10th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Weiss Ratings upgraded KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th.

KindlyMD Price Performance

NASDAQ NAKA opened at $4.31 on Friday. The firm has a market cap of $74.99 million, a PE ratio of -0.10 and a beta of 15.84. KindlyMD has a one year low of $4.13 and a one year high of $808.00. The stock’s 50 day simple moving average is $7.66 and its 200 day simple moving average is $12.25.

KindlyMD (NASDAQ:NAKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($15.20) EPS for the quarter. The business had revenue of $2.68 million for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%. As a group, equities analysts expect that KindlyMD will post -16.8 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO David F. Bailey acquired 104,833 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were purchased at an average cost of $4.84 per share, for a total transaction of $507,391.72. Following the transaction, the chief executive officer owned 3,120,361 shares of the company’s stock, valued at approximately $15,102,547.24. This represents a 3.48% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders acquired 191,448 shares of company stock valued at $992,908. 24.49% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NAKA. Alyeska Investment Group L.P. bought a new position in KindlyMD in the 4th quarter valued at $8,993,000. ParaFi Capital LP bought a new position in KindlyMD in the 3rd quarter valued at $443,055,000. Hunting Hill Global Capital LLC bought a new position in KindlyMD in the 4th quarter valued at $4,672,000. RK Capital Management LLC FL bought a new position in KindlyMD in the 3rd quarter valued at $239,052,000. Finally, Yorkville Advisors Global LP bought a new position in KindlyMD in the 3rd quarter valued at $231,942,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.